OBJECTIVES: Many existing healthcare interventions diffused before modern evidence-based standards of clinical- and cost-effectiveness. Disinvestment from ineffective or inappropriately applied practices is growing as a priority for international health policy, both for improved quality of care and sustainability of resource allocation. Australian policy stakeholders were canvassed to assess their perspectives on the challenges and the nature of disinvestment. METHODS: Senior health policy stakeholders from Australia were criterion and snow-ball sampled (to identify opinion leaders). Participants were primed with a potential disinvestment case study and took part in individual semistructured interviews that focused on mechanisms and challenges within health policy to support disinvestment. Interviews were taped and transcribed for thematic analysis. Participant comments were de-identified. RESULTS: Ten stakeholders were interviewed before saturation was reached. Three primary themes were identified. (i) The current focus on assessment of new and emerging health technologies/practices and lack of attention toward existing practices is due to resource limitations and methodological complexity. Participants considered a parallel model to that of Australia's current assessment process for new medical technologies is best-positioned to facilitate disinvestment. (ii) To advance the disinvestment agenda requires an explicit focus on the potential for cost-savings coupled with improved quality of care. (iii) Support (financial and collaborative) is needed for research advancement in the methodological underpinnings associated with health technology assessment and for disinvestment specifically. CONCLUSIONS: In this exploratory study, stakeholders support the notion that systematic policy approaches to disinvestment will improve equity, efficiency, quality, and safety of health care, as well as sustainability of resource allocation.
OBJECTIVES: Many existing healthcare interventions diffused before modern evidence-based standards of clinical- and cost-effectiveness. Disinvestment from ineffective or inappropriately applied practices is growing as a priority for international health policy, both for improved quality of care and sustainability of resource allocation. Australian policy stakeholders were canvassed to assess their perspectives on the challenges and the nature of disinvestment. METHODS: Senior health policy stakeholders from Australia were criterion and snow-ball sampled (to identify opinion leaders). Participants were primed with a potential disinvestment case study and took part in individual semistructured interviews that focused on mechanisms and challenges within health policy to support disinvestment. Interviews were taped and transcribed for thematic analysis. Participant comments were de-identified. RESULTS: Ten stakeholders were interviewed before saturation was reached. Three primary themes were identified. (i) The current focus on assessment of new and emerging health technologies/practices and lack of attention toward existing practices is due to resource limitations and methodological complexity. Participants considered a parallel model to that of Australia's current assessment process for new medical technologies is best-positioned to facilitate disinvestment. (ii) To advance the disinvestment agenda requires an explicit focus on the potential for cost-savings coupled with improved quality of care. (iii) Support (financial and collaborative) is needed for research advancement in the methodological underpinnings associated with health technology assessment and for disinvestment specifically. CONCLUSIONS: In this exploratory study, stakeholders support the notion that systematic policy approaches to disinvestment will improve equity, efficiency, quality, and safety of health care, as well as sustainability of resource allocation.
Authors: Judith E Fisher; Ying Zhang; Ingrid Sketris; Grace Johnston; Fred Burge Journal: Pharmacoepidemiol Drug Saf Date: 2011-11-14 Impact factor: 2.890
Authors: P Alison Paprica; Anthony J Culyer; Adam G Elshaug; Justin Peffer; Guillermo A Sandoval Journal: Int J Technol Assess Health Care Date: 2015-08-20 Impact factor: 2.188
Authors: Daniel J Niven; Kelly J Mrklas; Jessalyn K Holodinsky; Sharon E Straus; Brenda R Hemmelgarn; Lianne P Jeffs; Henry Thomas Stelfox Journal: BMC Med Date: 2015-10-06 Impact factor: 8.775
Authors: Gail MacKean; Tom Noseworthy; Adam G Elshaug; Laura Leggett; Peter Littlejohns; Joan Berezanski; Fiona Clement Journal: Int J Technol Assess Health Care Date: 2013-10 Impact factor: 2.188
Authors: Michael G Wilson; Moriah E Ellen; John N Lavis; Jeremy M Grimshaw; Kaelan A Moat; Joshua Shemer; Terry Sullivan; Sarah Garner; Ron Goeree; Roberto Grilli; Justin Peffer; Kevin Samra Journal: Syst Rev Date: 2014-12-11
Authors: Holly Gwyther; Rachel Shaw; Eva-Amparo Jaime Dauden; Barbara D'Avanzo; Donata Kurpas; Maria Bujnowska-Fedak; Tomasz Kujawa; Maura Marcucci; Antonio Cano; Carol Holland Journal: BMJ Open Date: 2018-01-13 Impact factor: 2.692